Mark McClellan - Johnson Johnson Independent Director

JNJ Stock  EUR 135.72  0.44  0.33%   

Director

Dr. Mark B. McClellan, M.D., Ph.D. is an Independent Director of the Company. He became the inaugural Director of the DukeRobert J. Margolis, MD, Center for Health Policy and the Margolis Professor of Business, Medicine and Policy at Duke University in January 2016. He is also a faculty member at Dell Medical School at The University of Texas in Austin. Previously, he served from 2007 to 2015 as a Senior Fellow in Economic Studies and as Director of the Initiatives on Value and Innovation in Health Care at the Brookings Institution. Dr. McClellan served as Administrator of the Centers for Medicare Medicaid Services for the U.S. Department of Health and Human Services from 2004 to 2006 and as Commissioner of the U.S. Food and Drug Administration from 2002 to 2004. He served as a member of the Presidents Council of Economic Advisers and as senior director for healthcare policy at the White House from 2001 to 2002 and, during President Bill Clintons administration, held the position of Deputy Assistant Secretary for Economic Policy for the Department of the Treasury. Dr. McClellan previously served as an associate professor of economics and medicine with tenure at Stanford University, where he also directed the Program on Health Outcomes Research. Dr. McClellan is the founding chair and a current board member of the ReaganUdall Foundation for the Food and Drug Administration, is a member of the National Academy of Medicine and chairs the Academys Leadership Consortium for Value and ScienceDriven Health Care, and cochairs the guiding committee of the Health Care Payment Learning and Action Network. since 2013.
Age 54
Tenure 11 years
Professional MarksPh.D
McClellan has received the Kenneth J. Arrow Award twice for Outstanding Research in Health Economics. A 1985 graduate of the University of Texas at Austin, Dr. McClellan earned his MD degree at the Harvard UniversityMassachusetts Institute of Technology Division of Health Science and Technology, and his MPA at the Kennedy School of Government at Harvard. He earned his PhD in Economics at MIT and completed his residency in internal medicine at Brigham and Women Hospital in Boston.

Similar Executives

Showing other executives

DIRECTOR Age

Anthony SainesCarsalesCom
N/A
Edwina GilbertCarsalesCom
N/A
Michael HolmesCarsalesCom
N/A
Donald EhrlichBG Foods
80
John SchwietersBG Foods
79
Linda FillerBG Foods
58
David WiadrowskiCarsalesCom
N/A
Raymond StevensBG Foods
55
Alan SpoonBG Foods
67
Kee WongCarsalesCom
N/A
Jeffrey BrowneCarsalesCom
63
Teri ListStollBG Foods
56
Chris PolitesCarsalesCom
N/A
Patrick OSullivanCarsalesCom
54
Elias ZerhouniBG Foods
67
Kim AndersonCarsalesCom
N/A
Walter LohrBG Foods
75
Johnson Johnson (JNJ) is traded on Munich Exchange in Germany and employs 29 people.

Johnson Johnson Leadership Team

Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman of the Board, CEO
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, Vice President General Counsel
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Director
Sandra Peterson, Group Worldwide Chairman
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Vice President - Investor Relations
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Ian Davis, Independent Director
Paulus Stoffels, Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Dominic Caruso, CFO, Vice President - Finance
Peter Fasolo, Vice President - Global Human Resources
Susan Lindquist, Independent Director

Johnson Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Johnson Stock please use our How to Invest in Johnson Johnson guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Johnson Stock analysis

When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Money Managers
Screen money managers from public funds and ETFs managed around the world
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.